Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease
Authors:
- 1 December 2021
- journal article
- letter
- Published by Elsevier in Gastroenterology
- Vol. 161 (6) , 2041-2043.e1
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- Leona M and Harry B Helmsley Charitable Trust
- Cedars-Sinai Medical Center Inflammatory Bowel and Immunobiology Research Institute
This publication has 7 references indexed in Scilit:
- Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel DiseaseGastroenterology, 2021
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsNew England Journal of Medicine, 2021
- Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic TherapiesGastroenterology, 2021
- Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant RecipientsTransplantation, 2021
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDGut, 2021
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19JAMA, 2021